[{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Ansun Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ansun Biopharm \/ Ansun Biopharm","highestDevelopmentStatusID":"1","companyTruncated":"Ansun Biopharm \/ Ansun Biopharm"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ansun Biopharm \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Ansun Biopharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Interim data on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures .

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 23, 2020

                          Lead Product(s) : Avasopasem manganese

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 21, 2020

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : New study will build on recent clinical evidence showing efficacy of DAS181 in improving symptoms of patients with severe COVID-19.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 15, 2020

                          Lead Product(s) : Sialidase L

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : In the first 14 days of study, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 02, 2020

                          Lead Product(s) : Sialidase L

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 27, 2020

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Renmin Hospital of Wuhan University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 06, 2020

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          January 18, 2019

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Paramyxoviridae Infections.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          August 19, 2013

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          December 04, 2012

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : DAS181 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Paramyxoviridae Infections.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          July 19, 2012

                          Lead Product(s) : DAS181

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank